Diabetic retinopathy (DR) is a medical condition of the eye, which is prevalent in a diabetic individual. It is mainly caused due to damage of the blood vessels of the light-sensitive tissue present at the back of the eye. Without timely treatment, the disease may lead to bleeding in the eyes, cloudy vision, and may even destroy the retina. DR is amongst the common cause of loss of vision in the diabetic population. From 1990 to 2010, DR holds the fifth position among the most common causes of preventable blindness and severe visual impairment.
The global diabetic retinopathy market was valued at $966 million in 2015, and is expected to reach $2,490 million by 2022, growing at a CAGR of 14.4% during the forecast period. The market is expected to witness significant growth during the forecast period due to increase in prevalence of diabetes worldwide, rise in geriatric population, growth in incidence of blindness due to diabetes, and augment in focus on awareness which facilitates early diagnosis to control the diseases. Although these factors garner the growth of the market, dearth of skilled ophthalmologists and extended approval time for drugs limit it. On the other hand, emergence of combined therapies for treatment of diabetic macular edema, and the emerging markets of the Asia-Pacific and LAMEA regions are projected to provide several opportunities for the market growth.
The diabetic retinopathy market is segmented on the basis of type, treatment type, and region. Based on type, the market is bifurcated into proliferative DR and diabetic macular edema (DME). On the basis of treatment type, diabetic retinopathy market is segmented into anti VEGF drug, steroid implants, laser surgeries, and vitrectomy. The market is analyzed based on four geographical regions, which include North America, Europe, Asia-Pacific, and LAMEA.
KEY BENEFITS FOR STAKEHOLDERS
This report provides an extensive analysis of the current and emerging market trends and dynamics in the global diabetic retinopathy market.
Comprehensive analysis of geographical regions is provided to determine the prevailing opportunities in the market.
This study provides the competitive landscape of the market to predict the competitive environment across geographies.
This report entails the detailed quantitative analysis of the current market and estimations from 2014 to 2022 to identify the prevailing opportunities.
Comprehensive analysis of factors that drive and restrict the market growth is provided in the report.
Region- and country-wise diabetic retinopathy market conditions are comprehensively analyzed in the report to understand the regional trends and dynamics.
Diabetic Retinopathy Market Key Segments:
By Type
Proliferative Diabetic Retinopathy
Diabetic Macular Edema (DME)
By Treatment Type
Anti VEGF Drug
Steroid Implants
Laser Surgeries
Vitrectomy
By Region
North America
U.S.
Canada
Mexico
Europe
France
Germany
UK
Italy
Spain
Rest of Europe
Asia-Pacific
Japan
China
India
Australia
South Korea
Rest of Asia-Pacific
LAMEA
Brazil
Saudi Arabia
South Africa
Rest of LAMEA
LIST OF KEY PLAYERS PROFILED IN THE REPORT
Abbott Laboratories
Alimera Science
Allergan plc
Ampio Pharmaceuticals.
Bayer AG
F. Hoffmann-La Roche
Novartis International AG
Pfizer
Regeneron Pharmaceuticals Inc.
Valeant Pharmaceutical
LIST OF OTHER PLAYERS IN THE VALUE CHAIN (These players are not profiled in the report. The same will be included on request)
Boehringer Ingelheim GmbH
KOWA Company, Ltd.
BCN Peptides S.A.
ThromboGenics NV
